Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I Sherman

Showing results (41-50 of 160) with videos related to

Pageof 16
Sort By:
Thyroid : Official Journal of the American Thyroid Association|December 6, 2011
Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinomaGary L Clayman, Garima Agarwal, Beth S Edeiken, et al.
Cancer|June 22, 2010
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinomaLibero Santarpia, Jeffrey N Myers, Steven I Sherman, et al.
Thyroid : Official Journal of the American Thyroid Association|December 20, 2002
Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinomaFarah Y Ghori, Danielle R Gutterman-Litofsky, Amin Jamal, et al.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2006
Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjectsWendy M Golden, Katie B Weber, Teri L Hernandez, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2018
Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid CarcinomaThomas J Giordano, Bryan R Haugen, Steven I Sherman, et al.
JCO Precision Oncology|February 20, 2026
Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid CarcinomaSarah Hamidi, Vivek Subbiah, Maria E Cabanillas, et al.
The Laryngoscope|February 14, 2013
Diagnosis and management of differentiated thyroid cancer using molecular biologyRobert L Witt, Robert L Ferris, Edmund A Pribitkin, et al.
Diabetes Care|January 28, 2010
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefitsDaniel J Drucker, Steven I Sherman, Fred S Gorelick, et al.
Cancer|February 25, 2003
Prognostic factors in patients with Hürthle cell neoplasms of the thyroidLuis Lopez-Penabad, Alice C Chiu, Ana O Hoff, et al.
Molecular Carcinogenesis|January 27, 2011
Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteinsSudhakar Chintharlapalli, Sabitha Papineni, Syng-Ook Lee, et al.
Pageof 16

Showing results (41-50 of 160) with videos related to

Sort By:
Pageof 16
Thyroid : Official Journal of the American Thyroid Association|December 6, 2011
Long-term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinomaGary L Clayman, Garima Agarwal, Beth S Edeiken, et al.
Cancer|June 22, 2010
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinomaLibero Santarpia, Jeffrey N Myers, Steven I Sherman, et al.
Thyroid : Official Journal of the American Thyroid Association|December 20, 2002
Socioeconomic factors and the presentation, management, and outcome of patients with differentiated thyroid carcinomaFarah Y Ghori, Danielle R Gutterman-Litofsky, Amin Jamal, et al.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2006
Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjectsWendy M Golden, Katie B Weber, Teri L Hernandez, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2018
Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid CarcinomaThomas J Giordano, Bryan R Haugen, Steven I Sherman, et al.
JCO Precision Oncology|February 20, 2026
Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid CarcinomaSarah Hamidi, Vivek Subbiah, Maria E Cabanillas, et al.
The Laryngoscope|February 14, 2013
Diagnosis and management of differentiated thyroid cancer using molecular biologyRobert L Witt, Robert L Ferris, Edmund A Pribitkin, et al.
Diabetes Care|January 28, 2010
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefitsDaniel J Drucker, Steven I Sherman, Fred S Gorelick, et al.
Cancer|February 25, 2003
Prognostic factors in patients with Hürthle cell neoplasms of the thyroidLuis Lopez-Penabad, Alice C Chiu, Ana O Hoff, et al.
Molecular Carcinogenesis|January 27, 2011
Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteinsSudhakar Chintharlapalli, Sabitha Papineni, Syng-Ook Lee, et al.
Pageof 16